The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death
Abstract
A recent, widely publicized meta-analysis of 42 clinical trials concluded that rosiglitazone was associated with an approximately 43% increased risk for myocardial infarction and an approximately 64% increased risk for cardiovascular death. The sensitivity of these conclusions to several methodological choices was not assessed. The meta-analysis was not based on a comprehensive search for all studies that might yield evidence about rosiglitazone's cardiovascular effects. Studies were combined on the basis of a lack of statistical heterogeneity, despite substantial variability in study design and outcome assessment. The meta-analytic approach that was used required the exclusion of studies with zero events in the treatment and control groups. Alternative meta-analytic approaches that use continuity corrections show lower odds ratios that are not statistically significant. We conclude that the risk for myocardial infarction and death from cardiovascular disease for diabetic patients taking rosiglitazone is uncertain: Neither increased nor decreased risk is established.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Russell Localio, A. (2007) · Statistics in Medicine · doi:10.1002/sim.2528 · Cited by 938
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073394 · Cited by 761
A general parametric approach to the meta‐analysis of randomized clinical trials
Whitehead, A., & Whitehead, J. (1991) · Statistics in Medicine · doi:10.1002/sim.4780101105 · Cited by 750
Bax, L., Yu, L.-M., Ikeda, N., Tsuruta, H., & Moons, K. G. (2006) · BMC Medical Research Methodology · doi:10.1186/1471-2288-6-50 · Cited by 514 · cited 1×
“We estimated the pooled odds ratio as our measure of effect size by using fixed-effects (for example, Mantel–Haenszel) and random-effects (DerSimonian–Laird) models (8).”
MethodSelf-citationFriedrich, J. O., Adhikari, N. K., & Beyene, J. (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-5 · Cited by 459
Stress ulcer prophylaxis in the critically III: A meta-analysis
Cook, D. J., Witt, L. G., Cook, R. J., & Guyatt, G. H. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90189-5 · Cited by 211
Rosiglitazone for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., Clar, C., & Ebrahim, S. H. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006063.pub2 · Cited by 129
Rosiglitazone and cardiotoxicity –weighing the evidence
Nathan, D. M. (2007) · New England Journal of Medicine · doi:10.1056/nejme078117 · Cited by 126 · cited 1×
“This observation, along with a more than 30% excess risk for myocardial ischemic events in rosiglitazone-treated patients reported in the meta-analysis conducted by GlaxoSmithKline (10), lends continued support to those questioning the cardiovascular safety of rosiglitazone (11, 12).”
Result
Cited by
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
Feinman, R. D., Pogozelski, W. K., Astrup, A., Bernstein, R. K., Fine, E. J., Westman, E. C., Accurso, A., Frassetto, L., Gower, B. A., McFarlane, S. I., et al. (2015) · Nutrition · doi:10.1016/j.nut.2014.06.011 · Cited by 912
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Fu, R., Gartlehner, G., Grant, M., Shamliyan, T., Sedrakyan, A., Wilt, T. J., Griffith, L., Oremus, M., Raina, P., Ismaila, A., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.08.010 · Cited by 730
Nissen, S. E., & Wolski, K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.207 · Cited by 594
Metadata
- Authors
- Diamond, G. A., Bax, L., & Kaul, S.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2007-10-16
- Volume
- 147
- Issue
- 8
- Pages
- 578-581
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2114978217
- Cited by
- 288
- References
- 13
- FWCI
- 31.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death. https://app.cochat.ai/papers/10.7326/0003-4819-147-8-200710160-00182
- The paper
- Diamond, G. A., Bax, L., & Kaul, S. (2007). Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-147-8-200710160-00182
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.